Organisation paid for research Program year 2024 Source: CMS Open Payments

UW Medicine

Neither a doctor nor a teaching hospital

Research payments

$602,439

11 payments

Through program year 2024, UW Medicine is reported as receiving $602,439 in research payments, across 11 payments.

By program year

2 rows

Year	Kind	Amount	Payments
2024	Research	$453,254	6
2023	Research	$149,185	5

Breakdown

Who paid Research payments · program years 2023–2024

AstraZeneca UK Limited $402,169 5 payments
Alexion Pharmaceuticals, Inc. $198,270 5 payments
AstraZeneca Pharmaceuticals LP $2,000 1 payment

Studies the money was for Research payments · program years 2023–2024

A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Docetaxel Versus Placebo + Docetaxel as Treatment for Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) $365,346 3 payments
A Phase 3, Double Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL 101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia in Treatment Naive Patients with Stage IIIa AL Cardiac Amyloidosis. $97,209 2 payments
A Phase 3, Randomized, Double Blind, Placebo Controlled, Multicenter Study of Ravulizumab in Adult and Adolescent Participants who have Thrombotic Microangiopathy (TMA) after Hematopoietic Stem Cell Transplant (HSCT). $73,256 1 payment
CAMBRIA-1 A Phase III, Open-Label,Randomised Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients with ER+/HER2 $36,823 2 payments
A Phase 3, Randomized, Double Blind, Placebo Controlled, Multicenter Study of Ravulizumab in Adult and Adolescent Participants who have Thrombotic Microangiopathy (TMA) after Hematopoietic Stem Cell Transplant (HSCT) $24,350 1 payment
A Phase 3, Double Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL 101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment Naive Patients with Stage IIIb AL Cardiac Amyloidosis. $3,454 1 payment
Treatment Patterns Outcomes and Patient Reported Quality of Life A Prospective Disease Registry of Patients with Mantle Cell Lymphoma Treated with Novel Agents $2,000 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.